-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In most glioblastomas, the cyclin D-CDK4/6-Rb pathway is activated.
Breast cancer
In order to effectively evaluate the potential impact of Abemaciclib on the overall survival (OS) of newly diagnosed glioblastoma, and at the same time to develop information about potential genomic biomarker associations, Abemaciclib is listed as an innovative glioblastoma therapy personalized A test group of the screening test (INSIGhT).
diagnosis
And explored the relationship between the efficacy of Abemaciclib and cyclin D-CDK4/6-Rb pathway genome changes.
However, compared with the control group (median 15.
The core conclusion of this RCT: Abemaciclib is well tolerated and prolongs PFS, but there is no evidence that compared with standard radiotherapy and chemotherapy, overall survival has improved.
Abemaciclib is well tolerated and prolongs PFS, but there is no evidence that compared with standard radiotherapy and chemotherapy, overall survival has improved.
Leave a message here